Synlogic

Synlogic

A company developing therapeutic probiotics that alter the human gut microbiome to treat diseases.

Synologic is a clinical-stage biopharmaceutical company developing living medicines to treat a range of metabolic diseases, inflammatory diseases, and cancers. The technology platform uses synthetic biology to engineer beneficial bacteria, or probiotics, that alter the composition of the gut microbiome to restore proper metabolic functions. The populations of bacteria comprising the gut microbiome play a critical role in regulating the human immune system, metabolic function, brain health, and more. The company was founded in 2007 and is headquartered in Boston, Massachusetts.

Clinical programs

The majority of the company's drug candidates are in pre-clinical testing, although its lead drug candidate is in phase 2 trials. Synlogic calls its probiotics Synthetic Biotics. The pipeline as of July, 2nd, 2018:

Disease Targeted
Stage of Development
Partner

Hepatic encephalopathy

Phase 2

None

Immune oncology (three programs)

Pre-clinical

None

Inflammatory bowel disease

Pre-clinical

AbbVie

Liver disease

Screening

None

Maple Syrup urine disease

Pre-clinical

None

Organic acidemias

Pre-clinical

None

Phenylketonuria (PKU)

Pre-clinical

None

Urea cycle disorder

Phase 1

None

Partnerships
AbbVie
Ginkgo Bioworks

In December 2017 Synlogic and Ginkgo Bioworks announced a collaboration to use the latter's industrial scale organism engineering platform to discover new drug candidates.

Mergers and Acquisitions

In May 2017 Synlogic entered into a merger agreement with Mirna Therapeutics under which Synlogic merged with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company continued under the Synlogic name.

Timeline

June 1, 2020
Synlogic, Inc. announces the publication in Nature Communications of preclinical data supporting its first clinical Immuno-oncology program.

People

Name
Role
LinkedIn

Chris Mondella

Investor

David Neafus

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Synlogic, Inc.
February 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Synlogic, Inc.
February 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of...
Synlogic, Inc.
January 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined...
Synlogic, Inc.
December 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Synlogic, Inc.
December 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Synlogic, Inc.
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Synlogic, Inc.
November 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Alex Keown
November 6, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace
June 1, 2020
BioSpace
SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.